Document and Entity Information - USD ($) $ in Millions |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2025 |
Feb. 25, 2026 |
Jun. 30, 2025 |
|
| Document Information [Line Items] | |||
| Document Type | 10-K | ||
| Document Annual Report | true | ||
| Document Period End Date | Dec. 31, 2025 | ||
| Document Fiscal Year Focus | 2025 | ||
| Document Transition Report | false | ||
| Entity Interactive Data Current | Yes | ||
| ICFR Auditor Attestation Flag | false | ||
| Amendment Flag | false | ||
| Document Fiscal Period Focus | FY | ||
| Documents Incorporated by Reference [Text Block] | Portions of the Registrant’s definitive proxy statement relating to the 2026 Annual Meeting of Stockholders, which will be filed with the Securities and Exchange Commission within 120 days after the end of the Registrant’s fiscal year ended December 31, 2025, are incorporated by reference into Part III of this Annual Report on Form 10-K. |
||
| Entity Registrant Name | Semnur Pharmaceuticals, Inc. | ||
| Entity Central Index Key | 0001913577 | ||
| Entity File Number | 001-41351 | ||
| Entity Tax Identification Number | 98-1659463 | ||
| Entity Incorporation, State or Country Code | DE | ||
| Current Fiscal Year End Date | --12-31 | ||
| Entity Well-known Seasoned Issuer | No | ||
| Entity Voluntary Filers | No | ||
| Entity Current Reporting Status | Yes | ||
| Entity Shell Company | false | ||
| Entity Filer Category | Non-accelerated Filer | ||
| Entity Small Business | true | ||
| Entity Emerging Growth Company | true | ||
| Entity Ex Transition Period | true | ||
| Entity Public Float | $ 0.5 | ||
| City Area Code | (650) | ||
| Local Phone Number | 422-7515 | ||
| Entity Address, Address Line One | 960 San Antonio Road | ||
| Entity Address, City or Town | Palo Alto | ||
| Entity Address, State or Province | CA | ||
| Entity Address, Postal Zip Code | 94303 | ||
| Entity Common Stock, Shares Outstanding | 230,209,142 | ||
| Document Financial Statement Error Correction | false | ||
| Auditor Name | PIPARA & CO LLP | ||
| Auditor Firm ID | 6841 | ||
| Auditor Location | New Delhi, India | ||
| Auditor Opinion | Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Semnur Pharmaceuticals, Inc. and subsidiaries (the “Company”) as of December 31, 2025 and 2024, the related consolidated statements of operations and comprehensive loss, stockholders' deficit, and cash flows, for each of the years then ended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows of the two years in the period ended December 31, 2025, in conformity with accounting principles generally accepted in the United States of America. |
||
| Common Stock [Member] | |||
| Document Information [Line Items] | |||
| Title of 12(b) Security | Common stock, par value $0.0001 per share | ||
| Trading Symbol | SMNR | ||
| Warrant [Member] | |||
| Document Information [Line Items] | |||
| Title of 12(b) Security | Warrants to purchase one share of common stock, each at an exercise price of $11.50 per share | ||
| Trading Symbol | SMNRW |